Document:

Exhibit 10.1

                              AMENDED AND RESTATED
                       SECURED CONVERTIBLE REVOLVING NOTE

$925,000                                                  Dated:  April 30, 2003
                                                    Maturity Date: June 30, 2003

     FOR VALUE RECEIVED, PharmaKinetics Laboratories, Inc., a Maryland
corporation ("Borrower"), hereby promises to pay to the order of Bioanalytical
Systems, Inc., an Indiana corporation, or its successors or permitted assigns
("Lender"), at the address specified in Section 11 herein, or at such other
place as Lender may direct, the principal amount (the "Principal Amount") of
Nine Hundred Twenty-Five Thousand United States Dollars ($925,000) (or such
lesser amount as shall equal the aggregate unpaid principal amount of the Loans
(as defined below) made by the Lender to the Borrower hereunder together with
interest thereon at the rate of interest and in the manner set forth herein.
This Amended and Restated Secured Convertible Revolving Note (this "Note")
amends and restates that certain Secured Convertible Revolving Note dated as of
November 14, 2002 (the "Original Note"), and the Original Note is hereby
superseded and replaced in its entirety. This Note shall be deemed to be a
modification of Indebtedness pursuant to Section 3(a) of the Security Agreement
(as defined below) and the Guaranty (as defined below).

     1.   Loans. This Note evidences certain advances and extensions of credit
made prior to the date hereof and, subject to the terms and conditions of this
Note, and subject to the availability of cash for such purposes and the
restrictions set forth in any agreement between Lender and its lenders, to be
made after the date hereof by Lender, in Lender's sole discretion, in favor of
Borrower (the "Loans"). The aggregate principal amount of the Loans shall not
exceed the Principal Amount. The Loans shall be evidenced by this Note and this
Note shall supersede and replace the promissory notes of Borrower in favor of
Lender dated June 13, 2002, June 26, 2002, July 25, 2002, August 9, 2002,
September 30, 2002, October 4, 2002, October 31, 2002 and November 14, 2002.
Borrower acknowledges that all Loans advanced prior to the date hereof are
accurately recorded on the schedule attached hereto (the "Loan Schedule") and
authorizes the Lender to record on the Loan Schedule the date and amount of each
additional advance hereunder and the date and amount of each repayment of
principal, provided, however, that any failure by Lender to record any such
information shall not relieve Borrower of its obligation to repay the
outstanding principal amount of such advances, accrued interest thereon, and any
other amount payable with respect thereto in accordance with the terms of this
Note.

     2.   Payments. The entire unpaid principal balance of this Note, and all
accrued and unpaid interest thereon and all fees and charges incurred in
connection therewith, shall be due and payable on June 30, 2003 (the "Maturity
Date").

     3.   Interest. The outstanding principal balance of this Note shall bear
interest at a rate equal to eight percent (8%) per annum. Interest shall be due
and payable for the exact number of days principal is outstanding and shall be
calculated on the basis of a three hundred sixty (360) day year. If any payment
required by this Note is not made within five (5) days of the date such payment
is due, this
<PAGE>

Note shall bear interest (computed and adjusted in the same manner, and with the
same effect, as interest hereon prior to maturity) after the due date at a rate
per annum equal to two percent (2%) above the rate that would otherwise be in
effect, until paid, and whether before or after the entry of judgment hereon.

     4.   Prepayment. Borrower may prepay all or any portion of the unpaid
balance of this Note, without premium or penalty, at any time and from time to
time; provided, however, that all sums received by Lender in respect of this
Note shall be applied by Lender in the following order (i) to any costs of
collection and expenses reimbursable by Borrower to Lender, (ii) to the payment
of interest, if any, due on the outstanding balance of this Note or so much
thereof as shall from time to time remain unpaid, and (iii) to reduce the
outstanding principal balance of this Note.

     5.   Conversion.

          (a)  The Lender may, at Lender's option, at any time, and from time to
     time, prior to payment in full of this Note, convert the outstanding unpaid
     balance of this Note and any interest accrued pursuant to Section 3 above
     but unpaid (the "Conversion Amount"), in whole or in part (but only into
     full shares), into fully paid and non-assessable shares of the common
     stock, $.005 par value of Borrower's common shares (the "Common Shares"),
     at a price of $0.1585 per Common Share, subject to adjustment pursuant to
     Section 5(b) hereof (the "Conversion Rate"). In order to exercise this
     conversion right, the Lender must send written notice of the conversion to
     Borrower at least two (2) days prior to the specified conversion date (a
     "Conversion Notice"). On the conversion date (or as soon thereafter as is
     reasonably practicable), Borrower shall issue to Lender a share certificate
     for the Common Shares acquired upon conversion.

          (b)  The Conversion Rate shall be subject to adjustment: (i) if
     Borrower at any time subdivides (by any stock split, stock dividend,
     recapitalization or otherwise) one or more classes of its outstanding
     Common Shares into a greater number of shares, in which case the Conversion
     Rate in effect immediately prior to the subdivision will be proportionately
     reduced; (ii) if Borrower at any time combines (by reverse stock split or
     otherwise) one or more classes of its outstanding Common Shares into a
     smaller number of shares, in which case the Conversion Rate in effect
     immediately prior to that combination will be proportionately increased; or
     (iii) upon the issuance by Borrower of Common Shares, or of rights,
     options, warrants, or other securities convertible into Common Shares, at a
     price per share that is less than the Conversion Rate, in which case the
     Conversion Rate shall be adjusted so that it is equal to such per share
     price.

          (c)  Notwithstanding any other provisions of this Section 5 to the
     contrary, the conversion rights of Lender shall be subject to compliance
     with all applicable federal and state securities laws, and Lender agrees to
     execute all required agreements and documents required by Borrower to
     establish compliance with such laws.
<PAGE>

          (d)  Borrower shall at all times reserve and keep available and free
     of preemptive rights out of its authorized but unissued Common Shares,
     solely for the purpose of issuance upon conversion of the Note, that number
     of Common Shares as shall from time to time be sufficient to effect the
     conversion of the Note, and if at any time the number of authorized but
     unissued Common Shares shall not be sufficient to effect the conversion of
     the Note, Borrower shall take the corporate action necessary to increase
     the number of its authorized Common Shares to a number sufficient for this
     purpose.

          (e)  Notwithstanding anything in this Note to the contrary, the rights
     granted to Lender by this Section 5 (the "Conversion Rights") shall not
     become effective unless and until the registered owners of 100% of the
     Class B Convertible Preferred Stock of the Borrower (the "Preferred
     Holders") have delivered written notice to the Borrower of the waiver of
     the Preferred Holders of the rights granted to the Preferred Holders
     pursuant to Section 5 of the PharmaKinetics Laboratories, Inc. Articles
     Supplementary dated April 17, 2000 in connection with the Conversion
     Rights.

     6.   Method of Payment. All payments of principal and interest hereunder
shall be paid by Borrower in United States Dollars by wire transfer of
immediately available funds or in such other manner or at such other place as
Lender shall direct.

     7.   Events of Default. Each of the following constitutes an "Event of
Default" hereunder:

          (a)  If the entire outstanding principal balance on this Note,
     together with any accrued and unpaid interest thereon, is not paid within
     five (5) days after the Maturity Date;

          (b)  If a default occurs under the Security Agreement (as defined
     below) or the Guaranty (as defined below) and is not cured within thirty
     (30) days of the occurrence thereof; or

          (c)  If Borrower applies for, consents to or acquiesces in the
     appointment of a trustee, receiver or other custodian for Borrower or any
     property or assets of Borrower, or makes a general assignment for the
     benefit of creditors; or, in the absence of such application, consent or
     acquiescence, a trustee, receiver or other custodian is appointed for
     Borrower or for a substantial part of the property or assets of Borrower
     and is not discharged within sixty (60) days; or any bankruptcy,
     reorganization, debt arrangement, or other case or proceeding under any
     bankruptcy or insolvency law, or any dissolution or liquidation proceeding,
     is commenced in respect of Borrower, and if such case or proceeding is not
     commenced by Borrower, it is consented to or acquiesced in by Borrower or
     if such case or proceeding is not vacated, stayed or dismissed within sixty
     (60) days of such commencement.

     8.   Remedies Upon an Event of Default. If an Event of Default under
Section 7(c) shall occur and be continuing, the entire unpaid amount of this
Note shall be immediately due and payable without presentment, demand, protest
or notice of any kind, all of which Borrower expressly waives, and Lender may
thereafter exercise from time to time any rights, powers and remedies available
to it
<PAGE>

under all applicable laws or in equity. If an Event of Default under Section
7(a) or Section 7(b) of this Note shall occur and be continuing, then Lender
may, at its option, exercise any one or more of the following rights and
remedies:

          (a)  Lender may declare the entire unpaid amount of this Note to be
     immediately due and payable without presentment, demand, protest or notice
     of any kind, all of which Borrower expressly waives; and

          (b)  Lender may exercise from time to time any rights, powers and
     remedies available to him under all applicable laws or in equity.

In addition, if any Event of Default has occurred Lender shall be entitled to
recover from Borrower all costs and expenses, including reasonable attorneys'
fees and disbursements and court costs, incurred in enforcing its rights
hereunder. The rights and remedies of Lender stated herein are cumulative to and
not exclusive of any rights or remedies otherwise available to Lender.

     9.   Security Interest. This Note and any extensions or renewals hereof,
are secured by the Security Agreement dated as of November 14, 2002 (the
"Security Agreement") by Borrower in favor of Lender and the Guaranty dated as
of November 14, 2002 (the "Guaranty") by PKLB Limited Partnership, a Maryland
limited partnership ("Guarantor"), in favor of Lender. The Guaranty is secured
by an Indemnity Deed of Trust (the "Deed of Trust") dated November 14, 2002 and
recorded among the Land Records of Baltimore City, Maryland, in Liber 3080, Page
390 by Guarantor in favor of Lender. Reference is made to the Security
Agreement, the Guaranty and Deed of Trust for a description of the nature and
extent of the security, rights, duties and obligations of Borrower and Guarantor
and the rights of Lender.

     10.  Usury Laws. It is the intention of Borrower and Lender to conform
strictly to all applicable usury laws now or hereafter in force, and any
interest payable under this Note shall be subject to reduction to an amount
which is the maximum legal amount allowed under the applicable usury laws as now
or hereafter construed by the courts having jurisdiction over such matters. The
aggregate of all interest (whether designated as interest, service charges,
points or otherwise) contracted for, chargeable, or receivable under this Note
shall under no circumstances exceed the maximum legal rate upon the unpaid
principal balance of this Note remaining unpaid from time to time. If such
interest does exceed the maximum legal rate, it shall be deemed a mistake and
such excess shall be canceled automatically and, if theretofore paid, rebated to
Borrower or credited on the principal amount of this Note, or if this Note has
been repaid, then such excess shall be rebated to Borrower.

     11.  Assignability. This Note and the rights and obligations hereunder
shall not be assignable or transferable, by operation of law or otherwise;
provided, however, this Note may be assigned in whole or in part by Lender to
any individual, corporation, partnership, limited partnership, limited liability
company or other entity controlled by Lender in Lender's sole and absolute
discretion and without the consent of Borrower.
<PAGE>

     12.  Notices. All notices and other communications given or made pursuant
hereto shall be in writing and shall be deemed to have been duly given or made
as of the date delivered or sent if delivered personally or sent by telecopier
or by prepaid overnight carrier to the parties at the following addresses (or at
such other addresses as shall be specified by the parties by like notice):

                  if to Lender:

                           Bioanalytical Systems, Inc.
                           2701 Kent Avenue
                           Purdue Research Park
                           West Lafayette, Indiana  47906
                           Attention:  Peter T. Kissinger, Ph.D.
                           Facsimile:  (765) 497-1102

                  with a copy to:

                           Ice Miller
                           One American Square Box 82001
                           Indianapolis, Indiana  46282-0002
                           Attention:  Stephen J. Hackman, Esq.
                           Facsimile:  (317) 236-2219

                  if to Borrower:

                           PharmaKinetics Laboratories, Inc.
                           302 West Fayette Street
                           Baltimore, Maryland  21201
                           Attention:  James M. Wilkinson, II, Ph.D.
                           Facsimile:  (410) 385-1957

                  with a copy to:

                           Strasburger & Price, LLP
                           901 Main Street
                           Dallas, Texas  75202-3794
                           Attention:  David K. Meyercord, Esq.
                           Facsimile:  (214) 651-4330

     13.  Representations and Warranties. Borrower represents and warrants to
Lender that (i) the execution, delivery and performance by Borrower of this Note
has been duly authorized by all necessary action by the partnership, (ii) this
Note constitutes the valid, binding and enforceable obligation of Borrower,
(iii) Borrower has no defense, right of setoff or counterclaim of any nature in
connection with this Note or the Security Agreement, (iv) the representations
and warranties of
<PAGE>

Borrower set forth in this Note and Security Agreement are true and correct as
of the date of this Note and (v) after giving effect to this Note, no Event of
Default has occurred and is continuing under this Note or the Security
Agreement.

     14.  Consent and Confirmation of Guarantor. Guarantor, which has guaranteed
repayment to Lender by Borrower of the debt created pursuant to this Note, (i)
consents to the transactions contemplated by this Note, (ii) confirms that its
guaranty remains in full force and effect as to the full amount of this Note
notwithstanding the changes made by this Note and (iii) acknowledges and agrees
that the obligations of Borrower under this Note shall continue in all respects
to constitute obligations of Borrower guaranteed by Guarantor under the Guaranty
and the Deed of Trust.

     15.  Effectiveness. This Note shall become effective as of April 30, 2003
(the "Effective Date"). On the Effective Date, the Original Note shall be
automatically amended as set forth herein. On and after the Effective Date, the
rights and obligations of Borrower, Lender and Guarantor shall be governed by
this Note. The rights and obligations of Borrower, Lender and Guarantor with
respect to the period prior to the Effective Date shall continue to be governed
by the provisions of the Original Note.

     16.  Integration; Confirmation. On and after the Effective Date, each
reference in the Note, Security Agreement and Guaranty or other document
delivered in connection with the Note to the "Note," or words of similar import
shall be deemed to be a reference to the Note as amended by this Note, and the
Note as so amended shall be read as a single, integrated document. Except as
amended herein, all other terms and provisions of the Security Agreement,
Guaranty and any other document delivered in connection with the Loan shall
continue in full force and effect and unchanged and are hereby confirmed in all
respects.

     17.  Miscellaneous.

          (a)  This Note shall in all respects be governed by and construed in
     accordance with the laws of the State of Indiana without regard to
     conflicts of law principles.

          (b)  Borrower waives presentment, notice and demand, notice of
     protest, notice of demand and dishonor, and notice of nonpayment of this
     Note.

          (c)  Lender shall not (by act, delay, omission or otherwise) be deemed
     to have waived any of its rights or remedies hereunder, or any provision
     hereof, unless such waiver is in writing signed by Lender, and any such
     waiver shall be effective only to the extent specifically set forth
     therein. A waiver by Lender of any right or remedy under this Note on any
     one occasion shall not be construed as a bar to or waiver of any such right
     or remedy which Lender would otherwise have had on any future occasion.
<PAGE>

          (d)  Wherever possible, each provision of this Note which has been
     prohibited by or held invalid under applicable law shall be ineffective to
     the extent of such prohibition or invalidity, but such prohibition or
     invalidity shall not invalidate the remainder of such provision or the
     remaining provisions of this Note.

          (e)  Wherever in this Note reference is made to Borrower or Lender,
     such reference shall be deemed to include, as applicable, a reference to
     their respective successors and assigns, legatees, heirs, executors,
     administrators and legal representatives, as applicable, and, in the case
     of Lender, any future Lender of this Note, in any case as permitted by this
     Note. Subject to Section 11, the provisions of this Note shall be binding
     upon and shall inure to the benefit of such successors, assigns, Lenders,
     legatees, heirs, executors, administrators and legal representatives, as
     applicable.
<PAGE>

     IN WITNESS WHEREOF, Borrower has executed and delivered this Note as of the
day and year first above written.

                                         PHARMAKINETICS LABORATORIES, INC.

                                         By: /s/ James M. Wilkinson, II
                                             ----------------------------------

                                         Printed: James M. Wilkinson, II
                                                  -----------------------------

                                         Its: President and CEO
                                              ---------------------------------

Acknowledged:

BIOANALYTICAL SYSTEMS, INC.

By: /s/ Douglas P. Wieten
    ---------------------------------

Printed: Douglas P. Wieten
         ----------------------------

Its: CFO
     --------------------------------

Confirmed and Consented to by:

PKLB, LIMITED PARTNERSHIP

By: PharmaKinetics Laboratories, Inc., its General Partner

    By: /s/ James M. Wilkinson, II
        ------------------------------------

    Printed: James M. Wilkinson, II
             -------------------------------

    Its:
         -----------------------------------
<PAGE>

SCHEDULE OF AMOUNTS ADVANCED AND PAYMENTS OR PREPAYMENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------
                                                                         Amount of
                      Amount of                   Principal Paid or   Unpaid Principal   Notation Made
     Date              Advance    Interest Rate        Prepaid            Balance             By
------------------------------------------------------------------------------------------------------
<S>                       <C>        <C>                <C>             <C>                <C>
June 13, 2002             8%         $100,000           $0.00           $100,000.00
------------------------------------------------------------------------------------------------------

June 26, 2002             8%         $100,000           $0.00           $200,000.00
------------------------------------------------------------------------------------------------------

July 25, 2002             8%         $100,000           $0.00           $300,000.00
------------------------------------------------------------------------------------------------------

August 9, 2002            8%          $50,000           $0.00           $350,000.00
------------------------------------------------------------------------------------------------------

September 30, 2002        8%          $57,857           $0.00           $407,857.61
------------------------------------------------------------------------------------------------------

October 4, 2002           8%          $15,000           $0.00           $422,857.61
------------------------------------------------------------------------------------------------------

October 31, 2002          8%          $15,608           $0.00           $438,465.69
------------------------------------------------------------------------------------------------------

October 31, 2002          8%         $130,000           $0.00           $568,465.69
------------------------------------------------------------------------------------------------------

November 14, 2002         8%         $100,000           $0.00           $668,465.69
------------------------------------------------------------------------------------------------------

November 27, 2002         8%          $75,000           $0.00           $743,465.69
------------------------------------------------------------------------------------------------------

November 30, 2002         8%          $15,157           $0.00           $758,622.74
------------------------------------------------------------------------------------------------------

December 31, 2002         8%          $24,098           $0.00           $782,721.53
------------------------------------------------------------------------------------------------------

January 31, 2003          8%          $38,611           $0.00           $821,332.65
------------------------------------------------------------------------------------------------------

February 20, 2003         8%          $35,000           $0.00           $856,332.65
------------------------------------------------------------------------------------------------------

February 26, 2003         8%          $35,000           $0.00           $891,332.65
------------------------------------------------------------------------------------------------------

February 28, 2003         8%          $25,852           $0.00           $917,184.93
------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

SCHEDULE OF AMOUNTS ADVANCED AND PAYMENTS OR PREPAYMENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------
                                                                         Amount of
                      Amount of                   Principal Paid or   Unpaid Principal   Notation Made
     Date              Advance    Interest Rate        Prepaid            Balance             By
------------------------------------------------------------------------------------------------------
<S>                       <C>        <C>                <C>             <C>                <C>

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

SCHEDULE OF AMOUNTS ADVANCED AND PAYMENTS OR PREPAYMENTS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------
                                                                         Amount of
                      Amount of                   Principal Paid or   Unpaid Principal   Notation Made
     Date              Advance    Interest Rate        Prepaid            Balance             By
------------------------------------------------------------------------------------------------------
<S>                       <C>        <C>                <C>             <C>                <C>

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------
</TABLE>Exhibit 10.2

                AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTE

$350,000.00                                                 As of April 30, 2002

     FOR VALUE RECEIVED, PHARMAKINETICS LABORATORIES, INC., a Maryland
corporation ("Maker"), hereby promises to pay to the order of Leslie B. Daniels
("Payee") the sum of Three Hundred Fifty Thousand and No/100 Dollars
($350,000.00) or such lesser amount as shall then equal the outstanding
principal amount hereof on June 30, 2003 (the "Maturity Date"), together with
interest accruing from the date hereof on the unpaid principal hereof at the
rate of eight percent (8%) per annum. All sums hereunder are payable to Payee at
the address specified in Section 7 hereof or such other address as Payee may
specify to Maker from time to time.

     1. Loans. This Convertible Promissory Note (this "Note") evidences certain
advances and extensions of credit made prior to the date hereof and shall
supersede and replace the promissory notes of Maker in favor of Payee dated
April 3, 2002, May 14, 2002, May 30, 2002 and June 5, 2002. This Note is the
amendment, restatement, renewal and extension of that certain Convertible
Promissory Note dated as of November 22, 2002, which is hereby superseded and
replaced in its entirety.

     2. Payments. The unpaid principal balance of this Note, plus all accrued
and unpaid interest on the outstanding principal hereof shall be due and payable
on the Maturity Date, subject to any prior conversion(s) of this Note, as
provided in this Note, and subject to the provisions hereof regarding the
acceleration of the maturity date of this Note.

     3. Prepayment. Maker may at any time prepay in whole or in part the unpaid
principal or accrued interest of this Note which has not been converted as
provided in this Note. Any payments on this Note shall be applied first to
unpaid accrued interest hereon, and then to unpaid principal hereof.

     4. Conversion.

          (a) Payee may, at Payee's option, at any time, and from time to time,
     prior to payment in full of this Note, convert the outstanding unpaid
     balance of this Note and any accrued but unpaid interest (the "Conversion
     Amount"), in whole or in part (but only into full shares), into fully paid
     and non-assessable shares of the common stock, $0.005 par value, of Maker
     (the "Common Shares"), at a price of $0.1585 per Common Share, subject to
     adjustment pursuant to Section 4(b) hereof (the "Conversion Rate"). In
     order to exercise this conversion right, Payee must send written notice of
     the conversion to Maker at least two (2) days prior to the specified
     conversion date (a "Conversion Notice"). On the specified conversion date
     (or as soon thereafter as is reasonably practicable), Maker shall issue to
     Payee a share certificate for the Common Shares acquired upon such
     conversion.

          (b) The Conversion Rate shall be subject to adjustment: (i) if Maker
     at any time subdivides (by any stock split, stock dividend,
     recapitalization or otherwise) one or more classes of its outstanding
     Common Shares into a greater number of shares, in which case the Conversion
     Rate in effect immediately prior to the subdivision will be proportionately
     reduced; (ii) if Maker at any time combines (by reverse stock split or
     otherwise) one or more classes of its outstanding Common Shares into a
     smaller number of shares, in which case the Conversion Rate in effect
     immediately prior to that combination will be proportionately increased; or
     (iii) upon the issuance by Maker of Common Shares, or of rights, options,
     warrants, or other securities convertible into Common Shares, at a price
     per share that is less than the Conversion Rate, in which case, the
     Conversion Rate shall be adjusted so that it is equal to such per share
     price.

          (c) Notwithstanding any other provisions of this Section 4 to the
     contrary, the conversion rights of Payee shall be subject to compliance
     with all applicable federal and state securities laws, and Payee agrees to
     execute all required agreements and documents required by Maker to
     establish compliance with such laws.

          (d) Maker shall at all times reserve and keep available and free of
     preemptive rights out of its authorized but unissued Common Shares, solely
     for the purpose of issuance upon conversion of this Note, that number of
     Common Shares as shall from time to time be sufficient to effect the
     conversion of this Note, and if at any time the number of authorized but
     unissued Common Shares shall not be sufficient to effect the conversion of
     this Note, Maker shall take the corporate action necessary to increase the
     number of its authorized Common Shares to a number sufficient for this
     purpose.

     5. Acceleration Upon Default. Failure to pay this Note or any installment
hereunder as it becomes due may, at the election of the holder hereof, without
notice, demand, presentment, notice of intent to accelerate, notice of
acceleration, or any other notice of any kind which are hereby waived, mature
the principal of this Note and all accrued but unpaid interest thereon, if any,
and, if the holder hereof makes such election, the same shall at once become due
and payable and subject to those remedies of the holder hereof. No failure or
delay on the part of the holder hereof in exercising any right, power or
privilege hereunder shall operate as a waiver thereof.

     6. Waiver. Maker hereby waives grace, demand, presentment for payment,
notice of nonpayment, protest, notice of protest, notice of intent to
accelerate, notice of acceleration and all other notices of any kind hereunder.

     7. Notices. All notices, claims, demands and other communications hereunder
shall be in writing and shall be deemed given upon (a) confirmation of receipt
of a facsimile transmission, (b) confirmed delivery by a standard overnight
courier, (c) when delivered by hand or (d) the expiration of five business days
after the day when mailed by registered or certified mail (postage prepaid,
return receipt requested), addressed to the respective parties at the following
addresses (or such other address for a party as shall be specified by like
notice):

     (a) If to Payee:

         Leslie B. Daniels
         1040 Fifth Avenue
         New York, New York 10028
         Facsimile:  (212) 319-0232

     (b) If to Maker:

         PharmaKinetics Laboratories, Inc.
         302 West Fayette Street
         Baltimore, Maryland 21201
         Attn:  James M. Wilkinson, II, Ph.D.
         Facsimile:  (410) 385-1957

     8. Costs and Attorney's Fees. Maker agrees to pay, in addition to all other
amounts owing hereunder, all actual expenses of collection of this Note, all
court costs and reasonable attorney's fees incurred by the holder hereof on
account of such collection.

     9. Headings; References. All headings used herein are used for convenience
only and shall not be used to construe or interpret this Note. Except where
otherwise indicated, all references herein to Sections refer to Sections hereof.

     10. Successors and Assigns. All of the covenants, stipulations, promises,
and agreements in this Note by or on behalf of Maker shall bind its successors
and assigns, whether so expressed or not.

     11. Governing Law. This Note shall be governed by the laws of the State of
Maryland, and the laws of such state (other than conflicts of laws principles)
shall govern the construction, validity, enforcement, and interpretation hereof,
except to the extent federal laws otherwise govern the validity, construction,
enforcement, and interpretation hereof.

     12. Maximum Interest Rate. Regardless of any provision contained herein, or
in any other document executed in connection herewith, the holder hereof shall
never be entitled to receive, collect, or apply, as interest hereon, any amount
in excess of the maximum rate of interest permitted to be charged from time to
time by applicable law, and in the event the holder hereof ever receives,
collects, or applies, as interest, any such excess, such amount which would be
excessive interest shall be deemed a partial prepayment of the principal hereof
and treated hereunder as such; and, if the principal hereof is paid in full, any
remaining excess shall forthwith be paid to Maker. In determining whether or not
the interest paid or payable, under any specified contingency, exceeds the
highest lawful rate, Maker and the holder hereof shall, to the maximum extent
permitted under applicable law, (a) characterize any nonprincipal payment as an
expense, fee, or premium rather than as interest, (b) exclude voluntary
prepayments and the effects thereof, and (c) spread the total amount of interest
throughout the entire contemplated term hereof; provided that if the
indebtedness evidenced hereby is paid and performed in full prior to the end of
the full contemplated term thereof, and if the interest received for the actual
period of existence thereof exceeds the maximum lawful rate, the holder hereof
shall refund to Maker the amount of such excess or credit the amount of such
excess against the principal hereof, and in such event, the holder hereof shall
not be subject to any penalties provided by any laws for contracting for,
charging, or receiving interest in excess of the maximum lawful rate.

     IN WITNESS WHEREOF, Maker has executed this Note as of the day and year
first above written.

                                      PHARMAKINETICS LABORATORIES, INC.

                                      By: /s/ James M. Wilkinson, II, Ph.D.
                                          ---------------------------------
                                          James M. Wilkinson, II, Ph.D.
                                          President and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]